ESMO Gastrointestinal Oncology最新文献_第7页

ESMO Gastrointestinal Oncology Pub Date : 2023-10-01 DOI: 10.1016/j.esmogo.2023.08.004

F. van Bömmel , T. Berg , F. Lordick

{"title":"Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC)","authors":"F. van Bömmel , T. Berg , F. Lordick","doi":"10.1016/j.esmogo.2023.08.004","DOIUrl":"https://doi.org/10.1016/j.esmogo.2023.08.004","url":null,"abstract":"<div><p>Immune checkpoint inhibition (ICI) has revolutionized cancer therapy, including treatment of hepatocellular carcinoma (HCC) which comprises 80%-90% of all liver cancers, the third most common cause of cancer-related death worldwide. The main targeted pathways are the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoints. Blockade of CTLA-4 with monoclonal antibodies leads to an activation and increase in effector T cells that can interact with tumor cells. Additionally, inhibitory regulatory T cells are reduced, leading to an immunosupportive tumor microenvironment. PD-1/PD-L1 inhibition reduces immunosuppression directly within the tumor tissue and reactivates the immune response to tumor cells. Recently, the HIMALAYA trial has shown that dual ICI with the CTLA-4-blocking antibody tremelimumab and the PD-L1-directed antibody durvalumab (STRIDE regimen) is superior to sorafenib regarding efficacy and safety in advanced HCC and has shown unprecedented long-term survival data for these patients. The combination of PD-L1-directed ICI (atezolizumab) and anti-vascular endothelial growth factor (bevacizumab) significantly improved outcomes compared to sorafenib and has been in clinical use since 2020. Looking at outcome measures for ICI, radiologically assessed endpoints such as progression-free survival and objective response rate only modestly correlate with overall survival. The modified RECIST criteria seem to better identify ICI responders in HCC compared to conventional imaging evaluation criteria. So far, predictive biomarkers in HCC and a robust understanding of the impact of underlying liver diseases are largely lacking. An accurate stratification of patients based on biomarkers and etiology has the potential to further improve outcomes in HCC.</p></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71779383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Molecular Basis of Pancreatic Cancer--Selected Issues 胰腺癌的分子基础——选题

ESMO Gastrointestinal Oncology Pub Date : 2002-01-01 DOI: 10.1080/1475956021000020206

R. Talar-Wojnarowska, A. Sasor, J. Strzelczyk, E. Małecka-Panas

引用次数: 1

Surgery for Inflammatory Bowel Diseases and Prevention of Gastrointestinal Malignancies 炎性肠病的外科治疗和胃肠道恶性肿瘤的预防

ESMO Gastrointestinal Oncology Pub Date : 2002-01-01 DOI: 10.1080/1475956021000015086

J. Sayfan

引用次数: 1

Down-regulation of E-cadherin and β-catenin in Helicobacter pylori Associated Gastritis and Gastric Carcinoma: An Immunohistochemical Study 幽门螺杆菌相关性胃炎和胃癌中E-cadherin和β-catenin下调的免疫组织化学研究

ESMO Gastrointestinal Oncology Pub Date : 2002-01-01 DOI: 10.1080/1475956021000015103

Mohamed M. Eida, Abd Elraouf El Deib, A. Saad, I. Perry, David Roland, M. Dixon, J. Jankowski

引用次数: 2

Preliminary Colorectal Cancer Screening Program Model in Hungary 匈牙利初步结直肠癌筛查项目模型

ESMO Gastrointestinal Oncology Pub Date : 2002-01-01 DOI: 10.1080/1475956021000020215

I. Rácz, A. Szabó, M. Goda, A. Oláh

引用次数: 4

Expression of Bombesin Family Ligands and Receptors in Human Gastric Cancer Tissues and Cell Lines. Bombesin家族配体和受体在人胃癌组织和细胞系中的表达。

ESMO Gastrointestinal Oncology Pub Date : 2002-01-01 DOI: 10.1080/14759560290029614

Yoon Kim, Hanhui Yang, S. Oh

{"title":"Expression of Bombesin Family Ligands and Receptors in Human Gastric Cancer Tissues and Cell Lines.","authors":"Yoon Kim, Hanhui Yang, S. Oh","doi":"10.1080/14759560290029614","DOIUrl":"https://doi.org/10.1080/14759560290029614","url":null,"abstract":"Purpose: Bombesin-like peptides are known to be important in the autocrine growth of a number of smlll cell lung cancer cell lines. The aim of this study was to investigate the extent of bombesin family ligands/receptors expression in human gastric cancer tissues and cell lines, and to evaluate the relationship between the expression of bombesin family Iigands/receptor and clinicopathologic parameters. Methods: We measured the expression of gstrin releasing peptide (GAP), neuromedin B (NMB), and their receptors, in human gastric cancer tissues and cell lines. Ligand and receptor mRNA studies were carried out on: 20 tumor and matched normal samples, and 9 gastric cell lines. The expression of mRNA of GRP/NMB, and their receptors, was examined by the reverse transcription-polymerase chain reaction (RT-PCR). Results: Expression of GRP, NMB and GRPR, NMBR mRNA was found in 55%, 100%, 40%, and 100% of gastric cancer tissue, respectively. GRP/GRPR co-expression was observed in 30% of gastric cancer tissues and expression of gastric cancer was higher than that of normal mucosa. GRP and GRPR were highly expressed in the differentiated type of gastric cancer. In gastric cancer cell lines, these peptides and receptors were expressed equally. Conclusion: The result demonstrate that GRP, NMB, GRPR, and NMBR were expressed in gastric cancer tissues and cell lines. This result suggests that these may have a role as growth factors in gastric cancer growth, and these peptides may act in an autocrine fashion as a morphogen in gastric cancer.","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76989426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiofrequency Ablation of Liver Tumours 肝肿瘤的射频消融

ESMO Gastrointestinal Oncology Pub Date : 2002-01-01 DOI: 10.1080/14759560290019804

John W. C. Chen, D. Mirza

引用次数: 0

Recurrent Upper Gastrointestinal Bleeding Caused by a Giant Brunneroma--Report of a Case Treated Endoscopically 巨大褐瘤所致复发性上消化道出血——内镜治疗1例报告

ESMO Gastrointestinal Oncology Pub Date : 2002-01-01 DOI: 10.1080/1475956021000018614

K. Yassin, E. Vlodavsky, R. Eliakim

引用次数: 1

Hyperplastic Polyps of the Colorectum--Do They Possess a Malignant Potential? 结直肠增生性息肉——是否具有恶性潜能?

ESMO Gastrointestinal Oncology Pub Date : 2002-01-01 DOI: 10.1080/1475956021000017057

S. Böhm

引用次数: 0

A Randomised Placebo Control Double-blind Trial of Ranitidine in Patients with Colorectal Hepatic Metastases: Survival Advantage in Patients with Poor Cell Mediated Immunity 雷尼替丁在结直肠癌肝转移患者中的随机安慰剂对照双盲试验:细胞介导免疫低下患者的生存优势

ESMO Gastrointestinal Oncology Pub Date : 2002-01-01 DOI: 10.1080/14759560290032746

J. King, J. Caplehorn, J. Seifert, A. Preketes, P. Clingan, D. Morris

引用次数: 0